Abstract
Introduction Therapies that target activating Egfr, Alk, Ros1 and other mutations have become first-line treatments that improve NSCLC patient’s life expectancy. Latin-American patients are poorly represented in clinical trials and in genomic databases, thus little is known about the prevalence of actionable mutations in this population. This study characterizes, for the first time, the somatic mutations found in 52 actionable genes, and describe a novel set of potentially actionable mutations, in NSCLC patients from Chile, Brazil and Peru, while correlating these genomic occurrences with relevant clinical, demographic and pathology aspects.
Methods 1732 subjects diagnosed with NSCLC were analyzed. DNA and RNA were sequenced using a 52 genes NGS panel. Mutations were annotated using the Variant Effect Predictor, COSMIC, OncoKB and the Cancer Genome Interpreter to categorize somatic mutations.
Results We found a total of 1713 mutations with 626 (36.5%) novel, potentially driver mutations. 66.1% of these novel mutations were predicted as Tier 1 driver mutations. Actionable mutations for Ret and Alk were more prevalent in Brazil than in Chile, whereas Met exon-14 skipping was significantly enriched in Chile. In Peru, Egfr is higher while Kras is lower. A high number of novels potentially driver mutations in know NSCLC actionable genes, such as Alk, Erbb2, Ret, Met, and Ros1, was found.
Conclusions The analysis of many Latin America subjects revealed a significant number of clinically actionable but also novel somatic mutations in cancer genes highlighting the importance of including less-represented populations in clinical trials and molecular studies.
Competing Interest Statement
GS, AB, RA, RAC, MF, LR, DA, RL, JC and PP were Pfizer Chile employees. HF, EDN, DNN, GPB, MGA, CF, GB, JF, MA, SC, OA, MLS, GR, CS, KM and SR received a grant and non-financial support for to perform this work for CEMP Pfizer Chile. Outside this work, HF discloses personal fees and non-financial support from Pfizer and BMS and non-financial support from AstraZeneca and Roche.
Clinical Trial
NCT03220230
Funding Statement
This work received support from the Chilean Government CORFO International Center of Excellence Program (Grant # 13CEE2-21602) and Thermo Fisher Scientific. The funding sources were not involved in the study design, the collection, analysis and interpretation of data; in the writing of the report, neither in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CONEP SEPN 510 Norte- Bloco A- 3DEGREE Andar- Edificio Ex-INAN, Unidade II - Ministerio da Saude Brasilia, DF 70750-521 BRAZIL Comite Etico Cientifico Av. Salvador 364, Servicio de Salud Metropolitano Oriente Providencia, SANTIAGO, RM 7500922 CHILE Comite de Etica Hospital Clinico Universidad de Chile Avenida Santos Dumont 999 Santiago, RM 8380456 CHILE Comite Etico Cientifico. Servicio de Salud Concepcion San Martin 1436 Concepcion, REGION DEL BIO BIO 4070038 CHILE Comite Institucional de Bioetica de VIA LIBRE(CIB) Jr. Paraguay 490, Cercado de Lima Lima, LIMA, PERU 01 PERU Comite de Etica en Investigacion del INEN Av. Angamos Este 2520, Surquillo 15038 Lima PERU Comite Institucional de Bioetica Via Libre Jr Paraguay 490 Lima PERU Comite Institucional de Etica en Investigacion Hospital Nacional Hipolito UNANUE Av. Cesar Vallejo 1390, El Agustino Lima PERU
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article (and its supplementary information files).
